Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceuticals USA

Most Recent Events

  • 26 Feb 2013 Secondary endpoint results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 09 Nov 2012 Results were presented at the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in November 2012.
  • 22 May 2012 Actual end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top